Volume 27, Number 3—March 2021
Dispatch
Antibody Responses 8 Months after Asymptomatic or Mild SARS-CoV-2 Infection
Table 1
Characteristic | Asymptomatic | Mildly symptomatic |
---|---|---|
Total no. persons |
7 |
51 |
Sex, no. (%) | ||
M | 5 (71.4) | 18 (35.3) |
F |
2 (28.6) |
33 (64.7) |
Age, y, median (IQR) |
25 (21–26) |
26 (22–40) |
Underlying disease, no. (%)† |
0 |
3 (5.9) |
Smoking status | ||
Smoker | 0 | 0 |
Ex-smoker | 1 (14.3) | 2 (3.9) |
Nonsmoker |
6 (85.7) |
49 (96.1) |
Signs/symptoms, no. (%) | ||
Febrile/chilling sense | NA | 8 (15.7) |
Myalgia | NA | 5 (9.8) |
Headache | NA | 13 (25.5) |
Cough | NA | 20 (39.2) |
Sputum | NA | 33 (64.7) |
Rhinorrhea | NA | 25 (49.0) |
Sore throat | NA | 3 (5.9) |
Chest discomfort/dyspnea |
NA |
4 (7.8) |
Duration of PCR positivity, d, median (IQR) |
29 (25–34) |
24 (19–34) |
Days from symptom onset to blood sampling, median (IQR)‡ | 231 (231–233) | 234 (231–234) |
*IQR, interquartile range; NA, not applicable. †One each: hypertension, diabetes mellitus, asthma. ‡For asymptomatic patients, time from the first PCR-positive result to blood sampling.
1These first authors equally contributed to this article.
Page created: December 22, 2020
Page updated: February 21, 2021
Page reviewed: February 21, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.